CN103228792A - PEG-干扰素λ1结合物 - Google Patents

PEG-干扰素λ1结合物 Download PDF

Info

Publication number
CN103228792A
CN103228792A CN2012800033678A CN201280003367A CN103228792A CN 103228792 A CN103228792 A CN 103228792A CN 2012800033678 A CN2012800033678 A CN 2012800033678A CN 201280003367 A CN201280003367 A CN 201280003367A CN 103228792 A CN103228792 A CN 103228792A
Authority
CN
China
Prior art keywords
peg
ifnλ1
ifn
binding substances
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800033678A
Other languages
English (en)
Chinese (zh)
Inventor
何南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanogen Pharmaceutical Biotechnology
Original Assignee
Nanogen Pharmaceutical Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanogen Pharmaceutical Biotechnology filed Critical Nanogen Pharmaceutical Biotechnology
Publication of CN103228792A publication Critical patent/CN103228792A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2012800033678A 2011-08-25 2012-03-01 PEG-干扰素λ1结合物 Pending CN103228792A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
VN201102222 2011-08-25
VN1-2011-02222 2011-08-25
PCT/US2012/027317 WO2013028233A1 (en) 2011-08-25 2012-03-01 Peg-interferon lambda 1 conjugates

Publications (1)

Publication Number Publication Date
CN103228792A true CN103228792A (zh) 2013-07-31

Family

ID=47746747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012800033678A Pending CN103228792A (zh) 2011-08-25 2012-03-01 PEG-干扰素λ1结合物

Country Status (9)

Country Link
EP (1) EP2748328A4 (enExample)
JP (1) JP2014525939A (enExample)
CN (1) CN103228792A (enExample)
AU (1) AU2012299423A1 (enExample)
BR (1) BR112014004302A2 (enExample)
CA (1) CA2846092A1 (enExample)
RU (1) RU2014111179A (enExample)
WO (1) WO2013028233A1 (enExample)
ZA (1) ZA201401159B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111065405A (zh) * 2017-09-08 2020-04-24 科学未来管理有限责任公司 口服生物利用度高的聚乙二醇化干扰素λ及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874592T3 (es) * 2016-02-19 2021-11-05 Eiger Biopharmaceuticals Inc Tratamiento de la infección por el virus de la hepatitis delta con interferón lambda
ES3015227T3 (en) 2017-03-16 2025-04-30 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
CN112245570A (zh) 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法
AU2022210179A1 (en) 2021-01-21 2023-09-07 Biosteed Gene Transformation Tech. Co., Ltd. Interferon-based cancer treatment method, and pharmaceutical combination
KR20230157947A (ko) 2021-01-21 2023-11-17 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 암 재발 방지를 위한 방법 및 약제학적 조합
CN120676955A (zh) 2022-12-09 2025-09-19 Dys免疫治疗公司 产生抗hiv特异性中和抗体和/或抗hiv细胞毒性t细胞的复合aids疫苗

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CN1381512A (zh) * 2002-01-15 2002-11-27 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
CN1927388A (zh) * 2004-09-10 2007-03-14 北京金迪克生物技术研究所 含有人干扰素的药物组合物
CN101002942A (zh) * 2007-01-08 2007-07-25 湖南大学 一种peg化脂质体纳米颗粒
US20080096252A1 (en) * 2005-10-04 2008-04-24 Zamost Bruce L Production and purification of il-29
US20080132681A1 (en) * 2005-06-03 2008-06-05 Ambrx, Inc. Human Interferon Molecules and Their Uses
CN102099051A (zh) * 2008-06-05 2011-06-15 津莫吉尼蒂克斯公司 利用聚乙二醇化的iii型干扰素治疗丙型肝炎

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CN1381512A (zh) * 2002-01-15 2002-11-27 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
CN1927388A (zh) * 2004-09-10 2007-03-14 北京金迪克生物技术研究所 含有人干扰素的药物组合物
US20080132681A1 (en) * 2005-06-03 2008-06-05 Ambrx, Inc. Human Interferon Molecules and Their Uses
US20080096252A1 (en) * 2005-10-04 2008-04-24 Zamost Bruce L Production and purification of il-29
US20100003722A1 (en) * 2005-10-04 2010-01-07 Zymogenetics, Llc Production and purification of il-29
CN101002942A (zh) * 2007-01-08 2007-07-25 湖南大学 一种peg化脂质体纳米颗粒
CN102099051A (zh) * 2008-06-05 2011-06-15 津莫吉尼蒂克斯公司 利用聚乙二醇化的iii型干扰素治疗丙型肝炎

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHEPPARD, P. ET AL.: "Accession NO：NP_742152，interleukin-29 precursor [Homo sapiens]", 《GENBANK DATABASE》, 21 August 2011 (2011-08-21) *
胡小剑等: "羧甲基化单甲氧基聚乙二醇的制备及其对a-干扰素的修饰", 《过程工程学报》, vol. 3, no. 2, 30 April 2003 (2003-04-30) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111065405A (zh) * 2017-09-08 2020-04-24 科学未来管理有限责任公司 口服生物利用度高的聚乙二醇化干扰素λ及其制备方法

Also Published As

Publication number Publication date
AU2012299423A1 (en) 2014-03-06
EP2748328A4 (en) 2015-03-04
WO2013028233A1 (en) 2013-02-28
RU2014111179A (ru) 2015-09-27
ZA201401159B (en) 2015-04-29
CA2846092A1 (en) 2013-02-28
JP2014525939A (ja) 2014-10-02
BR112014004302A2 (pt) 2017-06-20
EP2748328A1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
US8980245B2 (en) PEG-interferon λ1 conjugates and methods of treating viral infections
JP2980569B2 (ja) インターフェロン複合体
ES2207830T3 (es) Conjugados de polietilenglicol-interferon alfa para la terapia de infecciones.
TW570802B (en) Improved interferon polymer conjugates
CN103228792A (zh) PEG-干扰素λ1结合物
US20060029573A1 (en) Pegylated interferon alpha-1b
WO2012011836A1 (en) The new stable polyethylene glycol conjugate of interferon alpha, represented by one positional isomer
ES2386575T3 (es) Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
AU2008286742B2 (en) Protein-polymer conjugates
AU2013226944B2 (en) Inhibitory agent for body cavity fluid accumulation
KR100888371B1 (ko) 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
WO2013029062A1 (en) Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same
CN102724980A (zh) 蛋白-聚合物偶联物的治疗用途
WO2005085283A1 (ja) 修飾インターロイキン−１１及びそれを含有する医薬組成物
CN1544472A (zh) 支链聚乙二醇－干扰素及其制法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130731